Guest post by Joe Hoft at JoeHoft.com – republished with permission
The Opioid Settlement: A Bizarre Boomerang Back to Big Pharma
Republished with permission from AbleChild.
In a startling examination, it appears that billions earmarked from opioid settlements are being cleverly funneled back into the coffers of pharmaceutical titans and the psychiatric sector. With settlements now soaring to an eye-watering $56.9 billion, originally intended to tackle the opioid epidemic, there’s a conspicuous absence of accountability regarding the allocation of these funds.
While at least 70% of these funds are mandated to support “opioid remediation efforts,” which includes enhancing access to addiction treatments, there’s an unsettling twist. Many of these treatments consist of psychiatric medications produced by the same pharmaceutical companies implicated in the opioid crisis, often administered to vulnerable populations within prisons and mental health courts. This situation conveniently boosts the psychiatric drug and behavioral health industry, often with medications that carry black box warnings for suicide and other severe side effects. In essence, it’s a win-win for these massive industries.
Major players such as Purdue Pharma, Teva Pharmaceuticals, Johnson & Johnson, and Allergan are disbursing billions in settlements, yet they persist in manufacturing and distributing addiction treatment drugs. This creates a vicious cycle where Big Pharma profits from both the creation of and the so-called “solution” to the crisis.
What’s most concerning is the apparent lack of scrutiny surrounding this blatant conflict of interest. Despite the vast sums involved and the critical stakes of the opioid epidemic, there’s a conspicuous silence from regulatory bodies, advocacy groups, and the media. No thorough investigations have been launched to track how these settlement funds are funneled back to pharmaceutical companies through treatment initiatives. Instead of channeling resources into the MEDWATCH program and improving drug safety, the medical industrial complex has grand plans to utilize this money, ensuring it flows right back to Big Pharma and their psychiatric affiliates.
In a troubling pattern, the psychiatric and behavioral health sectors appear to be morphing into the primary repositories for opioid settlement funds. While these settlements were designed to mitigate the fallout of the opioid crisis, a substantial portion of the money is being redirected to mental health and addiction treatment services without any measurable outcomes.
Numerous states are allocating settlement funds to expand access to medication-assisted treatment (MAT) for opioid use disorders, fund residential treatment programs, and bolster mental health services. For instance, Virginia has earmarked $1.25 million for the Department of Corrections to hire social workers specializing in opioid use disorders and to develop substance use education programs for incarcerated individuals, inmates.
The surge of settlement funds into the psychiatric and behavioral health domain raises significant concerns regarding potential conflicts of interest. With billions at stake, there’s an inherent risk that treatment providers and pharmaceutical manufacturers could unduly shape fund allocation, prioritizing their own agendas over evidence-based methods that genuinely assist those impacted by the opioid crisis.
This concentration of funding within a single sector of healthcare not only narrows the array of strategies available to combat the opioid epidemic but also risks perpetuating a cycle of treatment that fails to address the fundamental societal issues contributing to substance abuse. The settlement plan fundamentally neglects the drug safety concerns that triggered the epidemic and overlooks the necessity of supporting the MEDWATCH program, which could regulate pharmaceutical companies and save lives. As these settlement funds continue to be allocated, it is essential to critically evaluate whether this apparent influx of resources into psychiatric and behavioral health services represents the most effective use of resources in the fight against the opioid crisis and in saving lives.
Be the Voice for the Voiceless
What can you do? Sign the Petition calling for federal hearings!
Donate! Every dollar you contribute serves as a powerful testament, a resounding affirmation that the struggles of these families will not be overlooked. Your generosity today will resonate through generations, safeguarding the rights and well-being of children. Don’t let another family navigate this journey alone. Donate now and join us in fostering a world where every child’s mind is nurtured, respected, and afforded the opportunity to flourish. As a 501(c)3 organization, your donation to AbleChild is not just an investment in the welfare of vulnerable children but also a tax-deductible contribution to a cause that transcends individual lives.
